Market news

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical library (DEL) screen. Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, licensed an inhibitor of the oncology target phosphoinositide 3- kinase alpha (Pl3K

Sanjiv Patel, Director, President, and CEO, on September 08, 2026, sold 48,199 shares in Relay Thera

Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ETMorgan Stanley 24th Annual Global Healthcare Conference on Wednesday

After skyrocketing 1,027%, Relay Therapeutics looks to fuel more gains.

Relay Therapeutics (RLAY) reported second quarter 2026 results, with revenue of US$0.35 million and a net loss of US$83.71 million. This provides investors with fresh data on this clinical stage biotech stock. See our latest analysis for Relay Therapeutics. The earnings release comes after a sharp share price recovery for Relay Therapeutics, with a 90 day share price return of 51.83% and a year to date share price return of 153.55%, while the 1 year total shareholder return is very large at...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Sanjiv Patel, Director, President and CEO, on August 17, 2026, sold 48,199 shares in Relay Therapeut

Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near a new 3-year high. Technical momentum is strong, but fundamentals show that revenue is expected to decrease by more...

Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clinical data from Phase 1/2 ReInspire trial in vascular anomalies at the ISSVA World Congress 2026 and opened expansion cohorts Continued execution of ongoing Phase 3 ReDiscover-2 trial in 2L breast cancer Approximately $911 million in cash, cash equivalents and in

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision

Relay Therapeutics (RLAY) has an average rating of buy and mean price target of $25.38, according to

Thomas Catinazzo, Chief Financial Officer, on July 06, 2026, sold 17,717 shares in Relay Therapeutic